Submit a comment
Citation Information: J Clin Invest. 1984;73(1):107-115. https://doi.org/10.1172/JCI111180.
Abstract
Changes in cytosolic free Ca may function as a second messenger in neutrophils. Since the plasma membrane seems to be a major regulator of intracellular Ca in many cells, we characterized an energy-dependent Ca transport system in plasma membrane-enriched fractions ("podosomes") from phorbol myristate acetate-stimulated guinea pig and human neutrophils. The active Ca transport system in guinea pig podosomes exhibited a high affinity for Ca (Michaelis constant [Km]Ca 280 +/- 120 nM) and a maximum velocity of 0.83 nmol Ca/mg protein per min. Uptake showed an absolute requirement for Mg ATP (Km ATP 67 microM), whereas other trinucleotides were inactive. Ca uptake was optimal at pH 7, was azide insensitive and temperature dependent. Vanadium, an inhibitor of the Ca/Mg ATPase of heart sarcolemma, inhibited Ca pump activity by 50% at 1 microM. Ca transport was not affected in a NaCl-containing medium, an observation arguing against the presence of a Na/Ca exchange system. Calmodulin at 0.5-10 micrograms/ml stimulated the Ca pumping activity of EGTA-washed podosomes. Calmodulin depletion decreased the affinity of the Ca pump for Ca (Km Ca 2.07 microM) and its readdition restored it (Km Ca 0.55 microM). ATP-dependent Ca transport by podosomes and phagocytic vesicles was inactivated by exposure to trypsin or to the nonpenetrating sulfhydryl reagent rho-chloromercuribenzene sulfonate. Human podosomes had a Ca uptake system with properties similar to those of the guinea pig. These findings demonstrate the presence of a Ca pump in the neutrophil plasma membrane, which is active at physiological concentrations of free cytosolic Ca. By changing Ca concentrations at the cell periphery, this pump could control various motile functions of the neutrophil, such as locomotion or degranulation.
Authors
H Lagast, P D Lew, F A Waldvogel
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)